Michelle Hoang, MD
Internal Medicine · Warren, NJNPI 1174967426
Payments from drug & device makers
Across 245 payments — averaging $12.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$666
- Amarin Pharma, Inc.$439
- AbbVie$325
- Lilly USA, LLC$227
- Merck$214
- Takeda Pharmaceuticals U.S.A., Inc.$146
- plus $981 from 24 others
What the payments were for
- Food & beverage$2,998100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 57 | $666 |
| Amarin Pharma, Inc. | 41 | $439 |
| AbbVie(2 entities) | 31 | $325 |
| Lilly USA, LLC | 18 | $227 |
| Merck | 17 | $214 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $146 |
| Boehringer Ingelheim | 9 | $117 |
| AstraZeneca | 8 | $100 |
| Kowa Pharmaceuticals America, Inc. | 6 | $78 |
| Teva Pharmaceuticals USA, Inc. | 6 | $77 |
| Johnson & Johnson | 5 | $70 |
| Amgen(2 entities) | 4 | $61 |
| Novartis | 4 | $55 |
| Pfizer | 4 | $52 |
| Dynavax Technologies Corporation | 3 | $51 |
| Esperion Therapeutics, Inc. | 3 | $40 |
| Exact Sciences | 2 | $40 |
| Abbott | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Avanir Pharmaceuticals, Inc. | 2 | $26 |
| Bausch Health US, LLC | 2 | $26 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
| GSK | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Radius Health, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Eisai Inc. | 1 | $13 |
| Althera Pharmaceuticals LLC | 1 | $11 |
How this compares
$2,998 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 57 | $83,060 |
| OzempicSemaglutide | 37 | $45,628 |
| EliquisApixaban | 21 | $20,038 |
| TrulicityDulaglutide | 13 | $18,506 |
| JanuviaSitagliptin Phosphate | 13 | $11,000 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $5,757 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $5,602 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $2,659 |
| Atorvastatin Calcium | 185 | $1,661 |
| Amlodipine Besylate | 159 | $1,182 |
| Gabapentin | 46 | $1,103 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 16 | $1,025 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $858 |
| Ezetimibe | 24 | $696 |
| Duloxetine Hcl | 28 | $602 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $117 | $83,06057 claims |
| Novo NordiskOzempic | $666 | $45,62837 claims |
| PfizerEliquis | $52 | $20,03821 claims |
| Lilly USA, LLCTrulicity | $227 | $18,50613 claims |
| MerckJanuvia | $214 | $11,00013 claims |
| GSKBreo Ellipta | $15 | $5,75714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Warren
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.